# Aria® (golimumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/golimumab

> Aria® (golimumab), sponsored by JOHNSON & JOHNSON (JNJ), received a complete response letter from the FDA; the decision is dated November 2, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Aria® (golimumab) |
| Codes | JNJ-4804 |
| Sponsor | JOHNSON & JOHNSON (JNJ) https://sec-api.dev/companies/jnj/catalysts |
| Indications | [with inflammatory conditions](https://sec-api.dev/indications/with-inflammatory-conditions), [moderate to severe rheumatoid arthritis](https://sec-api.dev/indications/moderate-to-severe-rheumatoid-arthritis), variety of inflammatory conditions |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### September 29, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125433 SUPPL-30 (Efficacy): submission_status AP, submission_status_date 20200929, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product SIMPONI ARIA (GOLIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125433%22
- openFDA Drugs@FDA: "BLA125433 SUPPL-31 (Efficacy): submission_status AP, submission_status_date 20200929, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product SIMPONI ARIA (GOLIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125433%22

### February 1, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125433 SUPPL-32 (Efficacy): submission_status AP, submission_status_date 20210201, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product SIMPONI ARIA (GOLIMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125433%22

### Apr 2024: topline data readout

- Status: completed, positive. Date confidence: month. Indication: moderate to severe rheumatoid arthritis.
- First seen 2025-09-22, last confirmed 2025-09-22.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-006012): "In April 2024 Alvotech announced positive top-line results from a confirmatory clinical study comparing efficacy, safety, and immunogenicity between its biosimilar candidate AVT05 and Simponi® (golimumab) in patients with moderate to severe rheumatoid arthritis." https://www.sec.gov/Archives/edgar/data/1898416/000117184325006012/exh_993.htm

### January 27, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: with inflammatory conditions.
- First seen 2025-01-27, last confirmed 2026-06-16.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-000421): "REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, Alvotech's proposed biosimilar to Simponi® and Simponi Aria® (golimumab), which are prescribed to treat a variety of inflammatory conditions." https://www.sec.gov/Archives/edgar/data/1898416/000117184325000421/exh_991.htm
- SEC prospectus (424B) (accession 0000930413-26-001864): "In January 2025, the FDA accepted our BLA for AVT05 as a proposed biosimilar to Simponi / Simponi Aria (golimumab) for the treatment of patients with inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis." https://www.sec.gov/Archives/edgar/data/1898416/000093041326001864/c116682_424b5.htm
- SEC prospectus (424B) (accession 0000930413-26-001857): "In January 2025, the FDA accepted our BLA for AVT05 as a proposed biosimilar to Simponi / Simponi Aria (golimumab) for the treatment of patients with inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis." https://www.sec.gov/Archives/edgar/data/1898416/000093041326001857/c116682_424b5.htm

### November 2, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-11-03, last confirmed 2025-11-03.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-006876): "REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations, a biosimilar candidate to Simponi® (golimumab)." https://www.sec.gov/Archives/edgar/data/1898416/000117184325006876/exh_991.htm

## Same indication

- [Biosimilar](https://sec-api.dev/pdufa/biosimilar) (ALVO)
- [Simponi® (simponi)](https://sec-api.dev/pdufa/simponi) (ALVO)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/golimumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Aria® (golimumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/golimumab

```bibtex
@misc{secapidev_pdufa_golimumab_20261116,
  title        = {Aria® (golimumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/golimumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_golimumab_20261116","title":"Aria® (golimumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/golimumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
